Comerica Bank lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 8.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,091 shares of the medical instruments supplier’s stock after selling 8,210 shares during the period. Comerica Bank’s holdings in Becton, Dickinson and were worth $18,115,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Janney Montgomery Scott LLC raised its position in Becton, Dickinson and by 35.3% during the second quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock worth $8,447,000 after acquiring an additional 11,300 shares during the last quarter. Bessemer Group Inc. raised its position in Becton, Dickinson and by 1.4% during the second quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock worth $190,827,000 after acquiring an additional 13,263 shares during the last quarter. State of Alaska Department of Revenue raised its position in Becton, Dickinson and by 5.8% during the second quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock worth $6,438,000 after acquiring an additional 1,819 shares during the last quarter. Boston Financial Mangement LLC raised its position in Becton, Dickinson and by 10.2% during the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock worth $10,218,000 after acquiring an additional 5,152 shares during the last quarter. Finally, Union Bankshares Corp raised its position in Becton, Dickinson and by 1.7% during the second quarter. Union Bankshares Corp now owns 22,335 shares of the medical instruments supplier’s stock worth $4,357,000 after acquiring an additional 381 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

WARNING: “Comerica Bank Cuts Holdings in Becton, Dickinson and Company (BDX)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/17/comerica-bank-cuts-holdings-in-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (NYSE BDX) opened at 195.34 on Friday. The firm’s 50-day moving average is $199.43 and its 200 day moving average is $191.33. The stock has a market capitalization of $44.45 billion, a P/E ratio of 56.57 and a beta of 1.06. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s revenue for the quarter was down 5.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.35 earnings per share. On average, analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.49%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s payout ratio is presently 83.43%.

In related news, EVP Ribo Alberto Mas sold 7,463 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $201.41, for a total transaction of $1,503,122.83. Following the transaction, the executive vice president now owns 29,323 shares of the company’s stock, valued at $5,905,945.43. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Linda M. Tharby sold 4,695 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now directly owns 18,670 shares in the company, valued at approximately $3,742,961.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 75,904 shares of company stock worth $15,242,688. Insiders own 1.40% of the company’s stock.

A number of research firms have recently weighed in on BDX. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Cowen and Company reissued an “outperform” rating and issued a $230.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. Barclays PLC reissued an “equal weight” rating and issued a $210.00 price objective (up previously from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, July 17th. Finally, Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price objective for the company from $210.00 to $180.00 in a research report on Friday, June 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $196.93.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.